Compare Novavax Inc (NVAX) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Packaging Corporation of America — how do they compare? Novavax Inc trades at $12.59 (market cap $1.82B), while Packaging Corporation of America trades at $229.05 (market cap $20.49B). The key difference: Packaging Corporation of America is far larger — about 11.3× Novavax Inc's market cap, and Packaging Corporation of America pays a 2.61% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Packaging Corporation of America for 45 Days on average.
| NVAX | PKG | |
|---|---|---|
Market Cap | $1.82B | $20.49B |
Volume | 6,198,505 | 493,499 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.56 | $257.43 |
52-Week Low | $6.22 | $191.68 |
Typical Hold Time | 59 Days | 45 Days |
Enterprise Value | $1.39B | $24.30B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Packaging Corporation of America (PKG) trades at $229.06, up 0.8% on the day, amid a bearish technical signal and mixed earnings performance. The stock shows strong profitability with a 7.26% net income margin and 14.79% ROE, though 2026 profit margins are projected to decline. Recent news highlights institutional buying and a steady dividend, while analyst consensus is a $272.43 price target with a 'Hold' bias.
PKG offers value through its dividend and stable business model but faces headwinds from cost pressures and negative cash flow trends. The stock's near-term performance hinges on Q3 2026 earnings results, with risks including margin compression and economic sensitivity. Upside exists if the company beats expectations and manages costs effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
